Mindray Revolutionizes the Way of Using Ultrasound with TE Air, Its First Wireless Handheld Ultrasound System

Mindray (SZSE: 300760), one of the world’s leading developers and providers of advanced medical devices and solutions, recently launched its first wireless handheld ultrasound system, the TE Air.

“Built from Mindray’s leading technologies, the TE Air has made a historic breakthrough in the image quality level of handheld ultrasound, integrating professional-level image quality into a small and light wireless system. Its premium performance and wireless portability allow clinicians to diagnose anytime and anywhere with confidence,” said Xujin He, General Manager of the Medical Imaging System Business Unit at Mindray.

Designed specifically to meet the demand of global healthcare professionals for a higher-quality portable ultrasound device that is easy to use in multiple medical environments and delivers crisp point-of-care ultrasound (POCUS) imaging, the TE Air revolutionizes the way of using ultrasound by transforming a complicated ultrasound system into a small size device, while retaining its ability to meet higher clinical requirements.

Powered by Mindray’s eWave platform and 2nd generation Single Crystal technology, the TE Air delivers high-quality images with low power consumption for ultimate performance. Meanwhile, with the features of dedicated exam presets and comprehensive imaging modes, the TE Air allows clinicians to conduct ultrasound examinations more efficiently and offers more accurate decision-making assistance.

The TE Air’s wire-free design and compact size that easily fits in a pocket, high-level disinfection tolerance, and flexible charging for extreme mobility, empower clinicians to overcome the challenges brought by unexpected mobile clinical scenarios. The unique Air Capsule doubles as a protective case and a portable wireless charger that keeps the device running all day, taking only 35 minutes to fast charge the device. With an IP68-level waterproof and dustproof design, the device is fully immersible for high-level disinfection, suitable for hospital infection control.

The TE Air App, available for Android and iOS, perfectly balances simplicity and efficiency by allowing one-handed operation in any location. The TE Air can connect with advanced devices such as the Mindray TEX20 Ultrasound System, enabling providers to overcome the limitations of cords and tight spaces while offering premium functionality. It can also seamlessly integrate with hospital information systems to help improve workflow. Furthermore, the de-identified data collected can be saved and shared to meet the needs of teaching, training, consultation, and case sharing.

Medical Device News Magazinehttps://infomeddnews.com
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy